Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption.
- Author:
Yanjuan HUANG
1
;
Zhanghong XIAO
1
;
Zilin GUAN
1
;
Zishan ZENG
1
;
Yifeng SHEN
1
;
Xiaoyu XU
1
;
Chunshun ZHAO
1
Author Information
- Publication Type:Journal Article
- Keywords: Bone metastasis; Bone targeting; Cisplatin; Osteolysis; Zoledronate
- From: Acta Pharmaceutica Sinica B 2020;10(12):2384-2403
- CountryChina
- Language:English
- Abstract: The "vicious cycle" established between tumor growth and osteolysis aggravates the process of breast cancer bone metastasis, leading to life-threatening skeletal-related events that severely reduce survival and quality of life. To effectively interrupt the "vicious cycle", innovative therapeutic strategies that not only reduce osteolysis but also relieve tumor burden are urgently needed. Herein, a bone-seeking moiety, alendronate (ALN), functionalized coordination polymer nanoparticles (DZ@ALN) co-delivering cisplatin prodrug (DSP) and antiresorptive agent zoledronate (ZOL)
